Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance
Explore this paper's citation graph
Summary
Resistance to PZA is caused mostly by mutations in the pncA gene, encoding pyrazinamidase, which converts the prodrug PZA to the active form, pyrazinoic acid.
- Type
- letter
- Published
- 2017-09-13
- Cited by
- 6
- References
- 19
- Access
- Open access
- OpenAlex
- https://openalex.org/W2754112331
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:31933257
Keywords
Pyrazinamide, Mycobacterium tuberculosis, Prodrug, Tuberculosis, Microbiology
References
- Systematic Review of Mutations in Pyrazinamidase Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Clinical Isolates
- Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
- Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.
- Validation of pncA Gene Sequencing in Combination with the Mycobacterial Growth Indicator Tube Method To Test Susceptibility of Mycobacterium tuberculosis to Pyrazinamide
- Prevention of False Resistance Results Obtained in Testing the Susceptibility of Mycobacterium tuberculosis to Pyrazinamide with the Bactec MGIT 960 System Using a Reduced Inoculum
- Mechanisms of Pyrazinamide Action and Resistance
- Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide
- Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand
- Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study
- Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy
- Tuberculosis in migrants from 106 countries to Italy, 2008–2014
- Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system.
- A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis
- Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes
Cited by
- Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance
- Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis
- Implementation of Whole Genome Sequencing of Tuberculosis Isolates in a Referral Center in Rome: Six Years’ Experience in Characterizing Drug-Resistant TB and Disease Transmission
- Enhancing diagnostic efficiency of pyrazinamide resistance in Mycobacterium tuberculosis via modified MGIT assay and genotypic correlation
- Issues in Mycobacterium tuberculosis Complex Drug Susceptibility Testing: Pyrazinamide
- Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: impact of false-positive BD MGIT 960 results and added value of sequencing for accurate diagnosis in a low-MDR-TB-incidence context
Related papers
- Tuberculosis: An Update for Clinicians
- Mutations Associated with Pyrazinamide Resistance in the Clinical Isolates of Mycobacterium tuberculosis
- Transcriptional Biomarkers of Differentially Detectable Mycobacterium tuberculosis in Patient Sputum
- Transcriptional signatures of Mycobacterium tuberculosis in mouse model of intraocular tuberculosis.
- Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature
- Progression to active tuberculosis, but not transmission, varies by M. tuberculosis lineage in The Gambia
- A simplified pyrazinamidase test for pyrazinamide drug susceptibility in Mycobacterium tuberculosis.
- Potential of Rapid Diagnosis for Controlling Drug-Susceptible and Drug-Resistant Tuberculosis in Communities Where Mycobacterium tuberculosis Infections Are Highly Prevalent